Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 367311
Licensor hereby grants to Licensee a co-exclusive right and license, with the right to grant sublicenses solely as set forth in this agreement, under the Licensor Intellectual Property and Licensorâ€™s rights in the Joint Intellectual Property to the extent necessary or useful to Manufacture the Compound and Product in the Field in the Territory for Development and Commercialization by Licensee in the Territory.
USAN – TEDUGLUTIDE
Therapeutic Claim – treatment of intestinal diseases characterized by chemical or surgical damage of the intestinal epithelium such as Short Bowel Syndrome (SBS) or damage to the intestinal epithelium due to disease (glucagon-like peptide-2 (GLP-2) analog)
Licensor Patent Rights shall mean Patent Rights, to the extent that they (a) Cover Licensor Know-How or are directly related to the Manufacture, use, Commercialization or Development of Compound or Product in the Field, and (b) are Controlled by Licensor, but shall not include Joint Patent Rights.
GATTEX is an analog of glucagon-like peptide 2, a naturally occurring hormone that regulates proliferation of the cells lining the small intestine. Licensor is independently investigating GATTEX as a potential treatment for short bowel syndrome, or SBS, and other indications, including Crohnâ€™s disease, chemotherapy-induced enteritis, necrotizing enterocolitis and various other gastrointestinal diseases.
IPSCIO Record ID: 286078
Product means all products which are Glucagon-Like Peptide-2 (GLP-2), and all analogues, fragments, derivatives, receptors and compositions thereof whether developed by Licensee and/or Licensor pursuant to the Sponsored Research Agreement or otherwise.
Basic Patents means (1) the United States patent application filed April 14, 1995 entitled â€œGlucagon-Like Peptide-2 and Its Therapeutic Useâ€ and includes (2) patents to be issued pursuant to (1) and all divisions, continuations in whole and in part, reissues, re-examinations, substitutes, extensions and foreign counterparts thereof.
Improvement Patents means (1) patent applications for those inventions that (a) arise from research that is sponsored by Licensor and performed by or on behalf of Licensors and (b) relates to Product or to a method of making, using or selling Product, and all divisions, continuations in whole and in part, reissues, re-examinations, substitutes, extensions and foreign counterparts thereof.
Patent Rights includes Basic Patents and Improvement Patents.
Trade Secrets means all information, expertise, technical assistance and other trade secrets developed by or for Licensor or Licensor relating to the manufacture, use or sale of Product and which constitute confidential information and which he discloses in writing to Licensee
IPSCIO Record ID: 28777
ALX-0600 may also be useful in treating other gastrointestinal conditions characterized by malabsorption, altered absorptive capacity and inflammation or deterioration of the intestinal wall. Examples of these conditions include inflammatory bowel disease, like Crohnâ€™s Disease, and intestinal mucositis in cancer patients.
IPSCIO Record ID: 314635
Compound means YH12852, which has the chemical structure set forth in this agreement, together with all analogs, derivatives, metabolites, stereoisomers, polymorphs, formulations, mixtures or compositions thereof, and any existing or future improved or modified versions of the foregoing developed by or on behalf of Licensee, its Affiliates or Sublicensees.
Licensor Patent Rights means all Patent Rights in the Territory that are Controlled by Licensor or any of its Affiliates as of the Effective Date or thereafter during the Term (other than Joint Patent Rights) that Cover any Compound or Product. The Licensor Patent Rights existing as of the Effective Date are set forth on Schedule 1.57; provided, however, that, if Licensor is acquired by a Third Party, â€œLicensor Patent Rightsâ€ shall exclude any Patent Rights that (a) are Controlled by such Third Party or the Affiliates of such Third Party (other than Licensor and Licensor Pre-Existing Affiliates) and (b) were not Controlled by Licensor or any of the Licensor Pre-Existing Affiliates immediately prior to the closing of such acquisition transaction; provided further that, if, after the closing of such acquisition, any such Licensor Excluded Affiliate has or acquires Control of any Patent Right that Covers the Development, Manufacture or Commercialization of any Compound or Product and that is used to Develop, Manufacture or Commercialize any such Compound or Product, such additional Patent Right that is Controlled by such Licensor Excluded Affiliate shall be included in Licensor Patent Rights.
9,890,138 – Diaminopyrimidine derivatives and processes for the preparation thereof
10,227,330 – Diaminopyrimidine derivatives and processes for the preparation thereof
9,850,227 – Diaminopyrimidine derivatives and processes for the preparation thereof
Licensee is a global pharmaceutical company offering one-stop custom synthesis services of active pharmaceutical products (APIs) and intermediates.
YH12852 is a novel, potent and highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. Other 5-HT receptor agonists with less 5-HT4 selectivity have been shown to successfully treat GI mobility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia and gastroparesis.
IPSCIO Record ID: 340300
Glucagon is a peptide hormone, produced by alpha cells of the pancreas. It works to raise the concentration of glucose and fatty acids in the bloodstream, and is considered to be the main catabolic hormone of the body. It is also used as a medication to treat a number of health conditions. GLP-1 and GLP-2 are identifiers. Glucagon binds to the glucagon receptor, a G protein-coupled receptor, located in the plasma membrane of the cell.
SBS is a complex chronic and severe condition associated with reduced or complete loss of intestinal function.